Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Staiger

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Leukemia|July 19, 2022
PARP14 is a novel target in STAT6 mutant follicular lymphomaMichael Mentz, William Keay, Carolin Dorothea Strobl, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Cancer Cell|June 4, 2026
Pathogenesis of diffuse large B cell lymphoma proteogenotypesJulius C Enssle, Björn Häupl, Arber Qoku, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|May 2, 2018
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|June 30, 2018
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Leukemia|July 19, 2022
PARP14 is a novel target in STAT6 mutant follicular lymphomaMichael Mentz, William Keay, Carolin Dorothea Strobl, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Cancer Cell|June 4, 2026
Pathogenesis of diffuse large B cell lymphoma proteogenotypesJulius C Enssle, Björn Häupl, Arber Qoku, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Nature Medicine|June 30, 2018
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|May 2, 2018
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Nature Medicine|June 30, 2018
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesBjoern Chapuy, Chip Stewart, Andrew J Dunford, et al.
Pageof 7